KALV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 2.3%, SMA50 1.51%, SMA200 15.02%). The stock’s 14-day RSI is 53.73 (neutral), while the ATR of 0.8 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.05% below its high and over 70.66% above its low. Average 10-day trading volume of 953.81 thousand shares is in line with the 3-month average of 975.54 thousand, indicating normal recent market interest.

KalVista Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.86. This means the shares are trading above this model’s fair value.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) closed at $17.14 USD, gaining $0.68 (4.13%) from the previous close of $16.46. The stock is currently mid-range between its 52-week high and low $9.23 and $19.00. With a market capitalization of about $866.36 million, KalVista Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.29). Key stats such as the average daily volume over the past year has been around 982.15 thousand shares, trading with heavier-than-usual volume. Headquartered in Cambridge, MA, KalVista Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Benjamin L. Palleiko, the company employs approximately 150 people and listed since April 09, 2015. KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs.

KalVista Pharmaceuticals, Inc. has 49.95 million shares outstanding. The public float is 27.73 million shares, elevated short interest at 22.71% of float. This equals 10.06 million shares. The short ratio is 5.68 days. Institutional investors hold 111.68% of the float. Insiders own 1.29%. Venrock Healthcare Capital Partners III, L.P. holds 5.30 million shares, Palleiko Benjamin L has 451.82 thousand shares and Yea Christopher has 226.70 thousand shares. Over the past six months, insider transactions show net selling. They sold 88.53 thousand shares across 20 transactions.

KalVista Pharmaceuticals, Inc. generated EPS of -$4.00 over the past year. Five-year average earnings growth is -17.63%. The latest quarter delivered EPS of -$0.92. The next quarter is forecast at $nan. Next year's EPS is expected at $12.21. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $37.00 to $19.00. The high target offers 115.87% upside. The low target suggests 10.85% downside. The mean target is $28.13. This offers 64.12% upside. KalVista Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 8.24%. The prior quarter beat by 23.08%. Over the last six quarters, Apple has recorded several small beats. These include -99.91% in September 05, 2024.

Our AI price prediction model suggests that KalVista Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected fall of -45.51%, reaching $9.34 by June 22, 2026, with a range of $8.50 to $10.04. 1-Year Outlook: Projected gain of 6.83%, with price at $18.31 by March 24, 2027, within a range of $17.67 to $19.08.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shares are flat -5.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows KalVista Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -4.48. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $26.00, suggesting 51.69% upside.

KalVista Pharmaceuticals, Inc. trades at a P/E ratio of -4.48, slightly below the S&P 500 average, with a price-to-sales ratio of 58.42 and a price-to-book ratio of 55.39 reflecting a rich premium to book value. The P/FCF stands at -5.51, also below market averages. Compared to sector medians, KalVista Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.